Rakesh Chopra, MD, of India’s Artemis Hospitals, discusses ASCO’s Role in global cancer care and the issues he finds most pressing.
Daniel Heng, MD, MPH, of the Tom Baker Cancer Centre and the University of Calgary, and Sumanta K. Pal, MD, of the City of Hope, discuss key findings presented at ASCO: adjuvant pazopanib vs placebo after nephrectomy in patients with locally advanced disease (the PROTECT Trial), and adjuvant sunitinib used to treat high-risk disease.
Lisa A. Carey, MD, of the University of North Carolina, and Richard S. Finn, MD, of UCLA Medical Center, discuss phase II overall survival findings on palbociclib in combination with letrozole vs letrozole alone for front-line treatment of ER+/HER2– advanced breast cancer. (Abstract 1001)
Matthew D. Hellmann, MD, of Memorial Sloan Kettering Cancer Center, discusses study findings on nivolumab ± ipilimumab in advanced small cell lung cancer, in the first report of a randomized expansion cohort. (Abstract 8503)
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Clifford A. Hudis, MD, ASCO’s current CEO, discuss the state of cancer care and the challenges that lie ahead.
David H. Henry, MD, of Pennsylvania Oncology Hematology Associates, outlines abstracts focusing on chemotherapy in locally advanced rectal cancer and immune-related toxicity, response to anti–PD-L1 blockade, and epacadostat plus pembrolizumab in lung cancer.
